<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495820</url>
  </required_header>
  <id_info>
    <org_study_id>MHBB-011-06F</org_study_id>
    <nct_id>NCT00495820</nct_id>
  </id_info>
  <brief_title>Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study</brief_title>
  <official_title>Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the efficacy of methylphenidate over placebo in
      treating apathy in patients with Alzheimer's dementia. Apathy is one of the earliest and most
      profound disturbances that occur in Alzheimer's dementia (AD).

      Hypotheses: 1. Methylphenidate (MPH) will improve apathy significantly more than placebo in
      AD.

      2. Successful treatment of apathy will improve Instrumental Activities of Daily Living
      (IADLs), and caregiver burden.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: Apathy is one of the earliest and most profound disturbances that occur in
      Alzheimer's dementia (AD). Based on promising preliminary data from our open-label pilot
      study we propose a double blind, placebo-controlled randomized clinical trial of
      methylphenidate for treatment of apathy in AD.

      Research Design: Randomized double blind, placebo-controlled study which will evaluate the
      effect of methylphenidate on apathy and also the impact of improvement of apathy on caregiver
      burden and functional status.

      Hypotheses: 1. Methylphenidate will improve apathy significantly more than placebo in AD.

      2. Successful treatment of apathy will improve Instrumental Activities of Daily Living
      (IADLs), and caregiver burden.

      Methodology: 60 patients with apathy in the context of AD will be recruited over the next
      three years. In our proposed study patients will be recruited from relevant clinics at the
      Omaha Veterans Affairs Medical Center (VAMC) including clinics in Geriatric Psychiatry,
      Neurology, Primary Care and Geriatric Medicine. 30 patients each with AD and apathy will be
      randomly assigned to placebo or MPH. All patients in the methylphenidate arm will be started
      at 5mg twice daily and titrated to 10mg twice daily at two weeks. Patients will be continued
      in this arm for 12 weeks followed by a 2-week discontinuation phase. Patients will be
      assessed on regular intervals using the Apathy Evaluation Scale, Instrumental Activities of
      Daily Living, Zarit Burden Scale and Mini Mental State Examination.

      Findings: None, the study is not complete.

      Clinical Relationships: While memory is the key cognitive problem in AD, apathy is the key
      behavioral problem. Apathy is characterized by indifference, disengagement, passivity, and
      lack of enthusiasm, interest, empathy and interpersonal involvement. Apathy is the most
      common, one of the earliest and probably the most persistent of behavioral problems in AD.
      Apathy is the most disturbing behavior to caregivers and has the greatest impact on
      functional status and caregiver burden.

      Despite this, apathy as a behavioral problem has largely been neglected. Most of the research
      directed towards behavioral problems in dementia is targeted towards more visible behaviors
      such as agitation, and psychosis. Remarkably, there are no published randomized, double
      blind, placebo controlled studies in the treatment of apathy associated with AD.

      Impact/Significance: Around 1.4 million veterans suffer from apathy in association with AD.
      Apathy is a strong predictor for functional decline and caregiver burden. Treatment of apathy
      is remarkably understudied and is absolutely critical to allow veterans to maximize their
      functional status, social engagement and quality of life, and thus delaying placement in
      assisted living or nursing home settings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apathy Evaluation Scale Score at 12 Weeks</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>The Apathy Evaluation Scale (AES) has been specifically developed to assess apathy and discriminate it from depression. This 18 item scale with score ranging from 18 to 72, assesses apathy in behavioral, cognitive and emotional domains over the previous four weeks. Higher scores indicate worsening apathy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini-mental State Examination (MMSE) at 12 Weeks</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Mini-mental State Examination (MMSE) is a commonly used screening measure for cognition with questions pertaining to orientation, registration, recall, visuo-spatial construction, attention span etc. Score on MMSE ranges from 0-30, higher scores indicating improving cognition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>The Clinical Global Impression scale is an observational scale of global evaluation, which assesses the change in degree of illness in relation to the original assessment. The severity sub-scale reported below ranges from 1-7 wherein higher scores indicate worsening severity of illness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Apathy</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Ritalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Standard inactive pill.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of dementia of the Alzheimer type (DSM-IV Text Revision (TR) criteria)

          2. Mini-mental state examination (MMSE) &gt;18, but &lt;29

          3. Apathy Evaluation Scale (AES) score of more than 40

          4. Ability to provide informed consent by either the patient or caregiver.

          5. If subjects are being treated with antidepressants, they should be on a stable dose of
             antidepressants for at least two months prior to the enrollment into the study.

          6. If subjects are being treated with cholinesterase inhibitors and memantine, they
             should be on stable dose of those medications at least four months prior to the
             enrollment into the study.

        Exclusion Criteria:

          1. Patient currently taking methylphenidate or hypersensitivity or prior significant
             adverse events with methylphenidate.

          2. Patients currently taking Adderall (amphetamine mixed salts) or Dexedrine
             (dextroamphetamine sulphate) or any other amphetamine product.

          3. Uncontrolled hypertension (BP &gt; 140/90) or tachycardia (100) at screening visit

          4. Patients with frontotemporal dementia

          5. Patients meeting criteria for Major Depressive Disorder on the Mini International
             Neuropsychiatric Inventory (MINI)

          6. Patients with active psychosis as determined by MINI

          7. Patients currently being treated with antipsychotics

          8. History of uncontrolled seizure disorder

          9. History of malignant hypertension, symptomatic cardiovascular disease, cardiomyopathy,
             known structural cardiac defect or medically unstable arrhythmias.

         10. History of Tourette's syndrome or presence of motor tics

         11. Patients with glaucoma

         12. Patients taking monoamine oxidase inhibitors (MAOIs)

         13. Patient taking clonidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prasad R. Padala</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Omaha</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105-1873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, Petty F. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010 Apr;18(4):371-4. doi: 10.1097/JGP.0b013e3181cabcf6.</citation>
    <PMID>20220576</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <results_first_submitted>January 21, 2014</results_first_submitted>
  <results_first_submitted_qc>October 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2015</results_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Apathy</keyword>
  <keyword>Dementia</keyword>
  <keyword>Methylphenidate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>60 subjects meeting the inclusion and exclusion criteria were recruited from outpatient clinics at the Nebraska Western Iowa Health Care System between 2006-2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>Methylphenidate
Methylphenidate: Subject will receive 5mg BID for two weeks then 10mg BID until week 12 of the study.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>Placebo
Placebo: Standard inactive pill.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Methylphenidate
Methylphenidate: Subject will receive 5mg BID for two weeks then 10mg BID until week 12 of the study.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>Placebo
Placebo: Standard inactive pill.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.5" spread="7.9"/>
                    <measurement group_id="B2" value="76.1" spread="8.4"/>
                    <measurement group_id="B3" value="76.6" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apathy Evaluation Scale</title>
          <description>Range: 18-72 Higher scores indicate worse apathy</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.9" spread="7.1"/>
                    <measurement group_id="B2" value="47.6" spread="5.8"/>
                    <measurement group_id="B3" value="49.7" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini-mental State Examination (MMSE)</title>
          <description>Range 0-30. Higher scores indicate better cognition</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="2.5"/>
                    <measurement group_id="B2" value="24" spread="2.6"/>
                    <measurement group_id="B3" value="23.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Mini-Mental State Examination (3MS)</title>
          <description>Range 0-100. Higher scores indicate better cognition</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.1" spread="9"/>
                    <measurement group_id="B2" value="82.6" spread="10"/>
                    <measurement group_id="B3" value="81.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Activities of Daily Living</title>
          <description>Range 0-24. Higher scores indicate better independence in performing activities of daily living.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.3" spread="2.7"/>
                    <measurement group_id="B2" value="22.9" spread="2.2"/>
                    <measurement group_id="B3" value="22" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The Executive Interview (EXIT-25)</title>
          <description>Range: 0-50, higher scores indicate worsening of executive function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.9" spread="6.3"/>
                    <measurement group_id="B2" value="16.8" spread="6.6"/>
                    <measurement group_id="B3" value="16.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Zarit Burden Scale</title>
          <description>Range 0-88. Higher scores indicate higher caregiver burden.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="13"/>
                    <measurement group_id="B2" value="25.3" spread="13.3"/>
                    <measurement group_id="B3" value="26.9" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression-severity (CGI-S)</title>
          <description>Range 0-7, higher scores indicating worsening of condition.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="0.6"/>
                    <measurement group_id="B2" value="5.1" spread="0.6"/>
                    <measurement group_id="B3" value="5.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apathy Evaluation Scale Score at 12 Weeks</title>
        <description>The Apathy Evaluation Scale (AES) has been specifically developed to assess apathy and discriminate it from depression. This 18 item scale with score ranging from 18 to 72, assesses apathy in behavioral, cognitive and emotional domains over the previous four weeks. Higher scores indicate worsening apathy.</description>
        <time_frame>At 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate Group</title>
            <description>Subjects randomized to this group received methylphenidate</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects randomized to this group received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Apathy Evaluation Scale Score at 12 Weeks</title>
          <description>The Apathy Evaluation Scale (AES) has been specifically developed to assess apathy and discriminate it from depression. This 18 item scale with score ranging from 18 to 72, assesses apathy in behavioral, cognitive and emotional domains over the previous four weeks. Higher scores indicate worsening apathy.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" spread="9.1"/>
                    <measurement group_id="O2" value="43.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mini-mental State Examination (MMSE) at 12 Weeks</title>
        <description>Mini-mental State Examination (MMSE) is a commonly used screening measure for cognition with questions pertaining to orientation, registration, recall, visuo-spatial construction, attention span etc. Score on MMSE ranges from 0-30, higher scores indicating improving cognition</description>
        <time_frame>At 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate Group</title>
            <description>Subjects randomized to this group received methylphenidate</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects randomized to this group received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mini-mental State Examination (MMSE) at 12 Weeks</title>
          <description>Mini-mental State Examination (MMSE) is a commonly used screening measure for cognition with questions pertaining to orientation, registration, recall, visuo-spatial construction, attention span etc. Score on MMSE ranges from 0-30, higher scores indicating improving cognition</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="2.7"/>
                    <measurement group_id="O2" value="23.6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.01</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression</title>
        <description>The Clinical Global Impression scale is an observational scale of global evaluation, which assesses the change in degree of illness in relation to the original assessment. The severity sub-scale reported below ranges from 1-7 wherein higher scores indicate worsening severity of illness.</description>
        <time_frame>At 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate Group</title>
            <description>Subjects randomized to this group received methylphenidate</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects randomized to this group received placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression</title>
          <description>The Clinical Global Impression scale is an observational scale of global evaluation, which assesses the change in degree of illness in relation to the original assessment. The severity sub-scale reported below ranges from 1-7 wherein higher scores indicate worsening severity of illness.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.1"/>
                    <measurement group_id="O2" value="4.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Methylphenidate Group</title>
          <description>Subjects randomized to this group received methylphenidate</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Subjects randomized to this group received methylphenidate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Increased blood pressure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size and short duration of the study are two important limitations of the study. All male subjects in the study also make it difficult to generalize the results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prasad Padala, MD, MS, Associate Director for Clinical Programs, GRECC</name_or_title>
      <organization>Central Arkansas Veterans Healthcare System</organization>
      <phone>5012572537</phone>
      <email>prasad.padala@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

